Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Wrocław. Najwięcej badań dotyczy: nieswoiste zapalenia jelit, białaczka, chłoniak, otyłość.
566 badań: 512 rekrutuje, 54 wkrótce zaczną.
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple…
+7A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
+6A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
+11A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
+15Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
+12A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
+15HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed…
+13A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
+10Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
+7A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
+5A Study of LAD603 in Adults With Alopecia Areata
Assessment of Respiratory Dysfunction in Obesity and the Use of IMT.
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
+7Confirmatory Clinical Study in Active Ulcerative Colitis
+1A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular…
+7A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
+8A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive…
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
+14Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
+1A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
+4Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.